NasdaqGS:CCXI

Stock Analysis Report

Executive Summary

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States.

Snowflake

Fundamentals

Excellent balance sheet with reasonable growth potential.

Risks

  • ChemoCentryx has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has ChemoCentryx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.4%

NasdaqGS:CCXI

0.5%

US Biotechs

-0.7%

US Market


1 Year Return

-38.5%

NasdaqGS:CCXI

-8.0%

US Biotechs

-0.5%

US Market

CCXI underperformed the Biotechs industry which returned -8.1% over the past year.

CCXI underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

CCXIIndustryMarket
7 Day-0.4%0.5%-0.7%
30 Day-17.6%1.0%-3.0%
90 Day-43.3%3.2%0.9%
1 Year-38.5%-38.5%-7.3%-8.0%1.7%-0.5%
3 Year44.8%44.8%9.3%5.6%39.5%30.4%
5 Year34.4%34.4%7.7%2.7%54.1%37.0%

Price Volatility Vs. Market

How volatile is ChemoCentryx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ChemoCentryx undervalued based on future cash flows and its price relative to the stock market?

5.47x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

ChemoCentryx's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

ChemoCentryx's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

ChemoCentryx is loss making, we can't compare its value to the US Biotechs industry average.

ChemoCentryx is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for ChemoCentryx, we can't assess if its growth is good value.


Price Based on Value of Assets

ChemoCentryx is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is ChemoCentryx expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

ChemoCentryx's revenue is expected to grow significantly at over 20% yearly.

ChemoCentryx's earnings are expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).

ChemoCentryx's revenue growth is expected to exceed the United States of America market average.

ChemoCentryx's earnings growth is expected to exceed the United States of America market average.

ChemoCentryx's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if ChemoCentryx will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has ChemoCentryx performed over the past 5 years?

21.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

ChemoCentryx does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare ChemoCentryx's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare ChemoCentryx's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if ChemoCentryx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if ChemoCentryx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if ChemoCentryx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is ChemoCentryx's financial position?


Financial Position Analysis

ChemoCentryx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

ChemoCentryx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

ChemoCentryx's level of debt (27.6%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0.1% vs 27.6% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 10.2x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

ChemoCentryx has sufficient cash runway for more than 3 years based on current free cash flow.

ChemoCentryx has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 74.2% each year.


Next Steps

Dividend

What is ChemoCentryx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate ChemoCentryx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate ChemoCentryx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as ChemoCentryx has not reported any payouts.

Unable to verify if ChemoCentryx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as ChemoCentryx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of ChemoCentryx's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Thomas Schall (60yo)

22.6yrs

Tenure

US$3,862,225

Compensation

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-ba ...


CEO Compensation Analysis

Thomas's remuneration is higher than average for companies of similar size in United States of America.

Thomas's compensation has increased whilst company is loss making.


Management Age and Tenure

3.0yrs

Average Tenure

57yo

Average Age

The tenure for the ChemoCentryx management team is about average.


Board Age and Tenure

7.3yrs

Average Tenure

63yo

Average Age

The tenure for the ChemoCentryx board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$85,845,42102 Nov 18
Vifor Pharma AG
EntityCompany
Shares7,343,492
Max PriceUS$11.69
SellUS$85,845,42118 Oct 18
GlaxoSmithKline plc
EntityCompany
Shares7,343,492
Max PriceUS$11.69

Ownership Breakdown


Management Team

  • Susan Kanaya (56yo)

    Executive VP

    • Tenure: 2.8yrs
    • Compensation: US$1.73m
  • Thomas Schall (60yo)

    Founder

    • Tenure: 22.6yrs
    • Compensation: US$3.86m
  • Markus Cappel (58yo)

    Senior VP

    • Tenure: 15.0yrs
    • Compensation: US$1.24m
  • Rajinder Singh (52yo)

    Senior VP & Head of Pharmaceutics

    • Tenure: 3.3yrs
    • Compensation: US$900.75k
  • Cass Kelleher

    Senior Vice President of Clinical Development

    • Tenure: 0.3yrs
  • Dalia Rayes

    Senior VP & Head of Commercial

    • Tenure: 0.6yrs

Board Members

  • Hank McKinnell (76yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: US$287.70k
  • Jim Tyree (66yo)

    Director

    • Tenure: 7.2yrs
    • Compensation: US$302.70k
  • Joe Feczko (70yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$287.70k
  • Edward Mocarski

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Craig Gerard

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Thomas Schall (60yo)

    Founder

    • Tenure: 22.6yrs
    • Compensation: US$3.86m
  • Henry Showell

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Richard Ransohoff

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Thomas Edwards (60yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$294.49k
  • Geoff Parker (54yo)

    Director

    • Tenure: 9.7yrs
    • Compensation: US$267.70k

Company Information

ChemoCentryx, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ChemoCentryx, Inc.
  • Ticker: CCXI
  • Exchange: NasdaqGS
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$391.441m
  • Shares outstanding: 58.25m
  • Website: https://www.chemocentryx.com

Number of Employees


Location

  • ChemoCentryx, Inc.
  • 850 Maude Avenue
  • Mountain View
  • California
  • 94043
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CCXINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2012
2CXDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2012

Biography

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and che ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/19 00:21
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.